Patrick Schulz, PhD

Director Cell Line Development, Biologicals Development at Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Training in Biotechnology (Hochschule Darmstadt), PhD in Biophysics at Max Planck Institute of Biophysics, Frankfurt, joining Boehringer Ingelheim in 2011 and pursuing several roles in biopharmaceutical development as Post-Doc, Lab Head Cell Line Development, Senior Project Leader for Process Commercialization and now heading the group for NBE Cell Line Development, focussing on state-of-the-art cell line engineering approaches, highly efficient stable cell line generation for biopharmaceutical production, applying latest technologies as e.g. Transposases and DNA editing tools, high throughput screening and lab automation.